Engineered exosomes cross the blood-brain barrier to reverse Alzheimer's pathology

Researchers engineered exosomes derived from young donor plasma by conjugating the rabies virus glycoprotein-targeting peptide (RVG-29) to their surface, creating vehicles that penetrate the blood-brain barrier and target neurons directly. In 3xTg transgenic mice modeling Alzheimer's disease, RVG-engineered exosomes (RVG-EXOs) markedly improved spatial learning, working memory, and novel object recognition while suppressing pathological Tau phosphorylation and accelerating amyloid-β clearance. At the molecular level, RVG-EXOs activated autophagy by inhibiting RPTOR expression, and single-cell RNA sequencing revealed a rebalanced brain cellular landscape: increased neuronal populations, restored inhibitory-to-excitatory neuron ratios, and suppression of disease-associated microglia in favor of homeostatic microglia. For longevity-focused readers, this finding opens a plausible path toward regenerative brain therapies that bypass systemic immunosuppression, though human validation remains the critical next milestone.